Maxim Sees Major Upside In These Biotech Stocks
In a recent report, analysts at Maxim Group discussed the biotechnology sector and gave their outlook for five names in the space. Here’s a rundown of what they had to say.
Athersys, Inc. (NASDAQ: ATHX)
Analysts believe that Athersys may have found a “sweet spot” for stroke treatment timing, as data from a phase II trial of MultiStem treatment one to two days after a stroke event is expected soon. Maxim has a Buy rating on Athersys and a $9.00 target for the stock.
Cytori Therapeutics Inc (NASDAQ: CYTX)
Cytori recently announced an emphasis on cost-cutting initiatives as it moves forward with its adipose-derives regenerative cell (ADRC) treatment trials. Analysts see big potential for the company in the scleroderma treatment space. Maxim has a Buy rating on Cytori and a $7.00 price target for the stock.
Ocata Therapeutics Inc (OTC: OCAT)
Analysts like the fundamental science and technology that Ocata brings to the table, but they are concerned about the near-term funding risk the company faces after it failed to close a $50 million funding raise in late 2014. Maxim has a Hold rating on Ocata.
OncoSec Medical Inc (OTC: ONCS)
Analysts like the results that OncoSec has seen so far in using up regulation of IL12 to drive cytotoxic T cells to attack tumors. Maxim has a Buy rating on OnceoSec and a $3.00 target for the stock.
Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)
Maxim believes that the company is undervalued following its merger with OnCor. Maxim’s Buy rating and $27.00 price target for Tekmira is based on an average of sum-of-the-parts, free cash flow and discounted cash flow valuation models.
Latest Ratings for ATHX
Date
Firm
Action
From
To
Apr 2014
First Analysis
Initiates Coverage on
Overweight
Dec 2013
Maxim Group
Maintains
Buy
Mar 2012
Piper Jaffray
Initiates Coverage on
Overweight
View More Analyst Ratings for ATHX
View the Latest Analyst Ratings
See more from Benzinga
Bank Of Russia Forecasts Oil
Dollar General ‘Still A Good Standalone Company’
10 Charts From Citi’s European Nike Survey
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Finance
Investment & Company Information
Continue at source:
Maxim Sees Major Upside In These Biotech Stocks
